Is DXCM a good stock to buy right now?

Based on our 6-factor quantitative model, DEXCOM INC (DXCM) receives a "Reduce" rating with a composite score of 42.6/100. It is ranked #2,476 out of 4,446 stocks. Key factor scores: Quality 50/100, Value 56/100, Momentum 38/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for DXCM?

DEXCOM INC (DXCM) has a "Reduce" rating and 2-star score. The composite score of 42.6 ranks it #2,476 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is DXCM in?

DEXCOM INC operates in the Healthcare sector (Medical Equipment industry) with a market cap of $24.00 billion. It is classified as a large-cap stock.

Does DXCM pay a dividend?

DXCM does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is DXCM's P/E ratio?

DXCM has a trailing P/E ratio of 34.52x. The Healthcare sector average is 23.6x. This above-average P/E reflects growth expectations or premium valuation.

How profitable is DXCM?

DXCM's quality factor score is 50/100. Gross margin: 59.1%. ROE: 25.6% vs sector average -43.5%. High margins suggest pricing power and competitive moats.

How is DXCM valued compared to peers?

DXCM's value factor score is 56/100 (higher = cheaper). Key multiples: P/E 34.5x, EV/EBITDA 31.6x. Valuation is roughly in line with peers.

What is DXCM's debt level?

DXCM's debt-to-equity ratio is 131%. Sector average: 32%. Moderate leverage is normal for established companies.

DXCM has a beta of 1.26, meaning it amplifies market moves. Stability score: 56/100.

Does DXCM have high short interest?

DXCM's short interest factor score is 16/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

DXCM Stock Analysis: Reduce (Score 42.6/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
DXCM	-2.53%	+2.89%	-5.56%	-3.54%	-4.87%	-	-	-
Industry Proxy XLV	-1.35%	+0.34%	-3.81%	-4.84%	+9.21%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	-2.46%	-0.71%	-5.90%	-3.18%	-34.40%	-	-	-
Alpha vs Sector	-1.17%	+2.55%	-1.75%	+1.30%	-14.08%	-	-	-

Metric	DXCM	Benchmark
P/E Ratio	34.5x	+46%
EV/EBITDA	31.6x	+398%
Price / Book	8.8x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	45.2x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	27.6x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	15.9x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.4x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.4x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.2x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
PFE PFIZER INC	49	50	59	48	11.1x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS
DXCM DEXCOM INC	43	50	56	38	34.5x	25.6%	59.1%	15.7%	20.4%	131.0x	$24.0B

Key Ratio	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Gross Margin %	0.6%	0.6%	0.6%	0.6%	0.6%	0.7%	0.7%	0.6%	0.6%	0.7%	0.7%
Operating Margin %	0.2%	0.2%	0.1%	0.2%	0.1%	0.1%	0.2%	0.1%	-0.2%	-0.1%	-0.1%
EBITDA Margin %	0.2%	0.2%	0.2%	0.2%	0.1%	0.1%	0.2%	0.1%	-0.2%	-0.0%	-0.1%
Net Margin %	0.2%	0.2%	0.1%	0.1%	0.1%	0.1%	0.3%	0.1%	-0.1%	-0.1%	-0.1%
FCF Margin %	-	-	-	-	-	-	14.4%	9.1%	5.4%	3.6%	0.1%
ROE %	0.3%	0.3%	0.3%	0.3%	0.2%	0.1%	0.3%	0.1%	-0.2%	-0.1%	-0.2%
ROA %	0.1%	0.1%	0.1%	0.1%	0.1%	0.0%	0.1%	0.0%	-0.1%	-0.1%	-0.2%
ROIC %	64.3%	26.2%	22.5%	22.8%	14.5%	9.3%	8.8%	7.5%	-27.4%	-11.0%	-26.7%

Key Ratio

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

Gross Margin %

0.6%

0.7%

0.6%

0.7%

Operating Margin %

0.2%

0.1%

0.2%

0.1%

0.2%

0.1%

-0.2%

-0.1%

EBITDA Margin %

0.2%

0.1%

0.2%

0.1%

-0.2%

-0.0%

-0.1%

Net Margin %

0.2%

0.1%

0.3%

0.1%

-0.1%

FCF Margin %

14.4%

9.1%

5.4%

3.6%

0.1%

ROE %

0.3%

0.2%

0.1%

0.3%

0.1%

-0.2%

-0.1%

-0.2%

ROA %

0.1%

0.0%

0.1%

0.0%

-0.1%

-0.2%

ROIC %

64.3%

26.2%

22.5%

22.8%

14.5%

9.3%

8.8%

7.5%

-27.4%

-11.0%

-26.7%

Line Item	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
	$4.4B	$4.7B	$4.0B	$3.6B	$2.9B	$2.4B	$1.9B	$1.5B	$1.0B	$719M	$573M	$402M
	—	$1.9B	$1.6B	$1.3B	$1.0B	$768M	—	—	—	—	—	—
	$2.6B	$2.8B	$2.4B	$2.3B	$1.9B	$1.7B	$1.3B	$932M	$664M	$492M	$378M	$278M
Gross Margin	59.1%	60.1%	60.5%	63.2%	64.7%	68.6%	66.4%	63.1%	64.4%	68.5%	66.0%	69.3%
	—	$1.3B	$1.3B	$1.2B	$1.0B	$811M	—	—	—	—	—	—
Research & Development	—	$599M	$552M	$506M	$484M	$517M	$360M	$274M	$417M	$185M	$156M	$138M
Depreciation	—	$40M	$40M	—	—	—	$67M	$49M	$47M	$26M	$15M	$11M
Total Operating Expenses	—	$1.9B	$1.8B	$1.7B	$1.5B	$1.4B	—	—	—	—	—	—
	$741M	$912M	$600M	$598M	$391M	$266M	$300M	$142M	-$186M	-$43M	-$64M	-$57M
EBIT	$741M	$912M	$600M	$598M	$391M	$266M	$300M	$142M	-$186M	-$43M	-$64M	-$57M
EBITDA	$769M	$951M	$640M	$598M	$391M	$266M	$383M	$217M	-$155M	-$10M	-$49M	-$46M
Operating Margin	16.7%	19.6%	14.9%	16.5%	13.4%	10.9%	15.5%	9.6%	-18.1%	-5.9%	-11.2%	-14.2%
EBITDA Margin	17.5%	20.4%	15.9%	16.5%	13.4%	10.9%	19.9%	14.7%	-15.0%	-1.4%	-8.5%	-11.5%
	—	—	—	$20M	$19M	$100M	$18M	$60M	$23M	$13M	$700K	$400K
	—	$1.1B	$709M	$710M	$391M	$174M	—	—	—	—	—	—
Income Tax Expense	—	$252M	$133M	$169M	$50M	$19M	-$252M	$3M	$600K	$2M	$700K	$100K
	$704M	$836M	$576M	$542M	$341M	$155M	$550M	$101M	-$127M	-$50M	-$66M	-$58M
Net Margin	15.7%	17.9%	14.3%	14.9%	11.7%	6.3%	28.5%	6.9%	-12.3%	-7.0%	-11.4%	-14.3%
	$2.14	$2.14	$1.46	$1.40	$0.88	$1.60	$1.46	$1.11	$-1.44	$-0.58	$-0.78	$-0.72
Diluted EPS	$2.14	$2.09	$1.42	$1.30	$0.82	$1.55	$1.46	$1.11	$-1.44	$-0.58	$-0.78	$-0.72
Weighted Avg Basic	—	390M	394M	386M	389M	97M	—	—	—	—	—	—
Weighted Avg Diluted	—	406M	413M	426M	428M	100M	—	—	—	—	—	—

Line Item

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

$4.4B

$4.7B

$4.0B

$3.6B

$2.9B

$2.4B

$1.9B

$1.5B

$1.0B

$719M

$573M

$402M

—

$1.9B

$1.6B

$1.3B

$1.0B

$768M

—

$2.6B

$2.8B

$2.4B

$2.3B

$1.9B

$1.7B

$1.3B

$932M

$664M

$492M

$378M

$278M

Gross Margin

59.1%

60.1%

60.5%

63.2%

64.7%

68.6%

66.4%

63.1%

64.4%

68.5%

66.0%

69.3%

—

$1.3B

$1.2B

$1.0B

$811M

—

Research & Development

—

$599M

$552M

$506M

$484M

$517M

$360M

$274M

$417M

$185M

$156M

$138M

Depreciation

—

$40M

—

$67M

$49M

$47M

$26M

$15M

$11M

Total Operating Expenses

—

$1.9B

$1.8B

$1.7B

$1.5B

$1.4B

—

$741M

$912M

$600M

$598M

$391M

$266M

$300M

$142M

-$186M

-$43M

-$64M

-$57M

EBIT

$741M

$912M

$600M

$598M

$391M

$266M

$300M

$142M

-$186M

-$43M

-$64M

-$57M

EBITDA

$769M

$951M

$640M

$598M

$391M

$266M

$383M

$217M

-$155M

-$10M

-$49M

-$46M

Operating Margin

16.7%

19.6%

14.9%

16.5%

13.4%

10.9%

15.5%

9.6%

-18.1%

-5.9%

-11.2%

-14.2%

EBITDA Margin

17.5%

20.4%

15.9%

16.5%

13.4%

10.9%

19.9%

14.7%

-15.0%

-1.4%

-8.5%

-11.5%

—

$20M

$19M

$100M

$18M

$60M

$23M

$13M

$700K

$400K

—

$1.1B

$709M

$710M

$391M

$174M

—

Income Tax Expense

—

$252M

$133M

$169M

$50M

$19M

-$252M

$3M

$600K

$2M

$700K

$100K

$704M

$836M

$576M

$542M

$341M

$155M

$550M

$101M

-$127M

-$50M

-$66M

-$58M

Net Margin

15.7%

17.9%

14.3%

14.9%

11.7%

6.3%

28.5%

6.9%

-12.3%

-7.0%

-11.4%

-14.3%

$2.14

$1.46

$1.40

$0.88

$1.60

$1.46

$1.11

$-1.44

$-0.58

$-0.78

$-0.72

Diluted EPS

$2.14

$2.09

$1.42

$1.30

$0.82

$1.55

$1.46

$1.11

$-1.44

$-0.58

$-0.78

$-0.72

Weighted Avg Basic

—

390M

394M

386M

389M

97M

—

Weighted Avg Diluted

—

406M

413M

426M

428M

100M

—

DEXCOM INC (DXCM) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does DEXCOM INC Do?

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California. DEXCOM INC (DXCM) is classified as a large-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Kevin R. Sayer and employs approximately 7,600 people, headquartered in SAN DIEGO, California. With a market capitalization of $24.0B, DXCM is one of the prominent companies in the Healthcare sector.

DEXCOM INC (DXCM) Stock Rating — Reduce (April 2026)

As of April 2026, DEXCOM INC receives a Reduce rating with a composite score of 42.6/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.DXCM ranks #2,476 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, DEXCOM INC ranks #310 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

DXCM Stock Price and 52-Week Range

DEXCOM INC (DXCM) currently trades at $64.11. The stock lost $1.57 (2.4%) in the most recent trading session. The 52-week high for DXCM is $89.98, which means the stock is currently trading -28.8% from its annual peak. The 52-week low is $54.11, putting the stock 18.5% above its annual trough. Recent trading volume was 2.1M shares, reflecting moderate market activity.

Is DXCM Overvalued or Undervalued? — Valuation Analysis

DEXCOM INC (DXCM) carries a value factor score of 56/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 34.52x, compared to the Healthcare sector average of 23.63x — a premium of 46%. The price-to-book ratio stands at 8.85x, versus the sector average of 2.75x. The price-to-sales ratio is 5.52x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, DXCM trades at 31.59x EV/EBITDA, versus 6.34x for the sector.

Overall, DXCM's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

DEXCOM INC Profitability — ROE, Margins, and Quality Score

DEXCOM INC (DXCM) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 25.6%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 11.1% versus the sector average of -33.1%.

On a margin basis, DEXCOM INC reports gross margins of 59.1%, compared to 71.5% for the sector. The operating margin is 16.7% (sector: -66.1%). Net profit margin stands at 15.7%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 20.4% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

DXCM Debt, Balance Sheet, and Financial Health

DEXCOM INC has a debt-to-equity ratio of 131.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 1.88x, suggesting adequate working capital coverage. Cash and equivalents stand at $1.84B.

DXCM has a beta of 1.26, meaning it is more volatile than the broader market — a $10,000 investment in DXCM would be expected to move 26.5% more than the S&P 500 on any given day. The stability factor score for DEXCOM INC is 56/100, reflecting average volatility within the normal range for its sector.

DEXCOM INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, DEXCOM INC reported revenue of $4.40B and earnings per share (EPS) of $2.14. Net income for the quarter was $704M. Gross margin was 59.1%. Operating income came in at $741M.

In FY 2025, DEXCOM INC reported revenue of $4.66B and earnings per share (EPS) of $2.14. Net income for the quarter was $836M. Gross margin was 60.1%. Revenue grew 15.6% year-over-year compared to FY 2024. Operating income came in at $912M.

In Q3 2025, DEXCOM INC reported revenue of $1.21B and earnings per share (EPS) of $0.73. Net income for the quarter was $284M. Gross margin was 60.5%. Revenue grew 21.6% year-over-year compared to Q3 2024. Operating income came in at $243M.

In Q2 2025, DEXCOM INC reported revenue of $1.16B and earnings per share (EPS) of $0.46. Net income for the quarter was $180M. Gross margin was 59.5%. Revenue grew 15.2% year-over-year compared to Q2 2024. Operating income came in at $213M.

Over the past 8 quarters, DEXCOM INC has demonstrated a growth trajectory, with revenue expanding from $1.00B to $4.40B. Investors analyzing DXCM stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

DXCM Dividend Yield and Income Analysis

DEXCOM INC (DXCM) does not currently pay a dividend. This is common among growth-oriented companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

DXCM Momentum and Technical Analysis Profile

DEXCOM INC (DXCM) has a momentum factor score of 38/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 26/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 16/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

DXCM vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, DEXCOM INC (DXCM) ranks #310 out of 838 stocks based on the Blank Capital composite score. This places DXCM in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing DXCM against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full DXCM vs S&P 500 (SPY) comparison to assess how DEXCOM INC stacks up against the broader market across all factor dimensions.

DXCM Next Earnings Date

No upcoming earnings date has been announced for DEXCOM INC (DXCM) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy DXCM? — Investment Thesis Summary

The quantitative profile for DEXCOM INC suggests caution. Momentum is weak at 38/100, a headwind for near-term performance.

In summary, DEXCOM INC (DXCM) earns a Reduce rating with a composite score of 42.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on DXCM stock.

Related Resources for DXCM Investors

Explore more research and tools: DXCM vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare DXCM head-to-head with peers: DXCM vs AZN, DXCM vs SLGL, DXCM vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

DexCom Inc (NASDAQ:DXCM) Fits the Affordable Growth Investment Strategy

DexCom (DXCM) Is Up 5.5% After New G7 Reimbursement Wins And CEO Transition Plans - What's Changed

Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time

DexCom (DXCM) Q2 2025 Earnings Call Transcript

DexCom (DXCM) Q3 2025 Earnings Call Transcript

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks

DEXCOM INC (DXCM) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does DEXCOM INC Do?

DEXCOM INC (DXCM) Stock Rating — Reduce (April 2026)

DXCM Stock Price and 52-Week Range

Is DXCM Overvalued or Undervalued? — Valuation Analysis

DEXCOM INC Profitability — ROE, Margins, and Quality Score

DXCM Debt, Balance Sheet, and Financial Health

DEXCOM INC Revenue and Earnings History — Quarterly Trend

DXCM Dividend Yield and Income Analysis

DXCM Momentum and Technical Analysis Profile

DXCM vs Competitors — Healthcare Sector Ranking and Peer Comparison

DXCM Next Earnings Date

Should You Buy DXCM? — Investment Thesis Summary

Related Resources for DXCM Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Intelligence Feed

DexCom Inc (NASDAQ:DXCM) Fits the Affordable Growth Investment Strategy

DexCom (DXCM) Is Up 5.5% After New G7 Reimbursement Wins And CEO Transition Plans - What's Changed

Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time

DexCom (DXCM) Q2 2025 Earnings Call Transcript

DexCom (DXCM) Q3 2025 Earnings Call Transcript